Different from what was described previously about SIRT5’srole in breast cancer, Greene et al. suggested that SIRT5 plays anoncogenic role through stabilizing GLS against ubiquitination andproteasomal degradation (Figure 4).85 This in turn supportsglutamine catabolism and the consequent obtainment of α-ketoglutarate,which enters the TCA cycle that leads to ATP production. This evidence concerns the gene SIRT5 and breast carcinoma.